Abstract 631P
Background
G-quadruplex (G4) structures can enhance propensity for DNA damage and they induce chromosome breaks, which activate homologous recombination (HR) repair pathway. CX-5461, a small molecule G4 stabilizer, selectively attacks HR-deficient cancer cells. We report the preliminary results of an open-label, multi-center, phase Ib expansion assessing CX-5461 in patients (pts) with solid tumours and BRCA2 and/or PALB2 mutation (NCT04890613).
Methods
CX-5461 was administered at two dose levels on Days 1 and 8 of a 28-day cycle to pts with pancreatic, prostate, breast or ovarian cancer (OC). Study comprises two cohorts: main cohort, with arm A (250 mg/m2) and B (325 mg/m2) enrolling pts with BRCA2 / PALB2 mutations, and exploratory cohort incorporating arm C (250 mg/m2) and D (325 mg/m2) for OC pts with BRCA1/ HR mutations. Primary objective is to determine recommended phase II dose of CX-5461. Secondary objectives: assessment of safety, tolerability and its anti-tumor activity.
Results
Of 28 pts enrolled, 22 have completed at least one cycle and were evaluable for DLT. Arm A included 2 OC pts, 5 breast cancer and 2 pancreatic cancer and Arm C and D: 10 and 3 OC pts. Among 22 pts, 36% had BRCA1 somatic, 14% BRCA1 germline, 4.5% somatic/germline BRCA1, 32% BRCA2 germline, 9% PALB2 germline and 4.5% HR mutations. Pts were heavily pretreated with median number of 6 lines (2-10): 77% prior platinum, 41% bevacizumab and 86% PARPi. Pts received median number of 4 doses (2-36) of CX-5461. Overall grade 3/4 adverse events (AE) were reported in 50%. Eight (36%) pts had grade 3/4 AE related to CX-5461. Five (23%) had grade 3 AE of special interest: 2 palmar-plantar erythrodysesthesia, 2 photosensitivity, 1 ocular photosensitivity; no grade 4 AE. Of the fifteen pts evaluable for response, 40% achieved clinical benefit with stable disease (SD) as best response. Of OC pts with SD (n=5), 3 had BRCA1 somatic, 1 BRCA1 germline and 1 HR mutations. All had previously received platinum and PARPi and two had duration of response > 6 months.
Conclusions
This Phase 1b study shows acceptable clinical tolerability and early signals of activity for CX-5461, including post PARP inhibition. Photosensitivity was manageable by preventive measures. Genomic data on resistance mechanisms is being analyzed.
Clinical trial identification
NCT04890613.
Editorial acknowledgement
Legal entity responsible for the study
UHN.
Funding
Senhwa.
Disclosure
H. Han: Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: OncLive; Financial Interests, Institutional, Local PI: Zymeworks, Arvinas, AbbVie, Daiichi Sankyo, Marker therapeutics, Pfizer, SeaGen, Quantum Leap Healthcare Collaborative, Celcuity, Mersana, Senwha. G. Shapiro: Financial Interests, Institutional, Other, Research funding to Dana-Farber Cancer Institute for conduct of investigator-initiated clinical trials.: Pfizer; Financial Interests, Institutional, Other, Research funding to Dana-Farber Cancer Institute for conduct of investigator-initiated clinical trial.: Eli Lilly; Financial Interests, Personal, Advisory Board, Additional research funding through a Sponsored Research Agreement, paid to Dana-Farber Cancer Institute: Merck KGaA/EMD-Serono; Financial Interests, Personal, Advisory Board: Bicycle Therapeutics, Boehringer Ingelheim, ImmunoMet, Blueprint Medicines, Kymera Therapeutics, Janssen, Xinthera; Financial Interests, Institutional, Other, Research funding through a Sponsored Research Agreement paid to Dana-Farber Cancer Institute: Tango Therapeutics; Financial Interests, Institutional, Other, Research funding through a Sponsored Research Agreement, paid to Dana-Farber Cancer Institute: Bristol Myers Squibb; Financial Interests, Institutional, Local PI: Exelixis, Cyteir, AbbVie, Incyte, AstraZeneca, Novartis, Amgen; Financial Interests, Institutional, Funding, For investigator-initiated clinical trials: Pfizer; Financial Interests, Personal and Institutional, Local PI: Bayer, Boehringer Ingelheim, Syros; Financial Interests, Institutional, Funding, For investigator-initiated clinical trial: Lilly; Financial Interests, Institutional, Coordinating PI: Cyclacel; Other, Patent: Dosage regimen for sapacitabine and seliciclib, issued to Geoffrey Shapiro and Cyclacel Pharmaceuticals: Cyclacel; Other, Pending patent: Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition, with Liam Cornell, PhD (Dana-Farber Cancer Institute): Dana-Farber Cancer Institute. L.S. Rosen: Financial Interests, Institutional, Funding, PI at UCLA Health Hem/Onc for Inspirna trial, Institution receives research funding: Inspirna. T. Chao: Financial Interests, Personal, Full or part-time Employment: Senhwa Biosciences, Inc.; Financial Interests, Personal, Stocks/Shares: Tracon Pharmaceuticals; Financial Interests, Personal, Stocks/Shares: BioLineRx. C. Huang: Financial Interests, Personal, Full or part-time Employment: Senhwa Biosciences; Non-Financial Interests, Leadership Role: Senhwa Biosciences. V. Bowering: Non-Financial Interests, Advisory Role, Nurses Advisory board - Lynparza: AstraZeneca; Non-Financial Interests, Advisory Role, Nurses Advisory Role-Niraparib: GSK. All other authors have declared no conflicts of interest.
Resources from the same session
672P - Inference failure with synthetic arms: Empirical application to phase III oncology trials
Presenter: Alexander Decruyenaere
Session: Poster session 01
673P - Project Optimus for dose optimization: Implementation strategies for your trial from the statistician’s standpoint
Presenter: Miguel Pereira
Session: Poster session 01
674P - Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
Presenter: Sebastian Albers
Session: Poster session 01
675P - Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Presenter: Lin Shen
Session: Poster session 01
678TiP - A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Presenter: Charlotte Lemech
Session: Poster session 01
679TiP - Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors
Presenter: Debashis Sarker
Session: Poster session 01
680TiP - A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Presenter: Anna Minchom
Session: Poster session 01
681TiP - A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies
Presenter: Lee Rosen
Session: Poster session 01
682TiP - A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Presenter: Shigehiro Koganemaru
Session: Poster session 01